Jane Street’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $64.9M | Buy |
145,300
+32,200
| +28% | +$15M | 0.01% | 897 |
|
|
2025
Q4 | $51.3M | Buy |
113,100
+59,500
| +111% | +$25.6M | 0.01% | 931 |
|
|
2025
Q3 | $21M | Sell |
53,600
-12,600
| -19% | -$5.27M | ﹤0.01% | 1623 |
|
|
2025
Q2 | $29.5M | Buy |
66,200
+21,300
| +47% | +$9.82M | 0.01% | 1103 |
|
|
2025
Q1 | $21.8M | Sell |
44,900
-28,200
| -39% | -$13.1M | 0.01% | 1217 |
|
|
2024
Q4 | $29.4M | Buy |
73,100
+43,300
| +145% | +$20.1M | 0.01% | 989 |
|
|
2024
Q3 | $13.9M | Sell |
29,800
-27,100
| -48% | -$13M | ﹤0.01% | 1588 |
|
|
2024
Q2 | $26.7M | Sell |
56,900
-15,600
| -22% | -$6.77M | 0.01% | 1072 |
|
|
2024
Q1 | $30.3M | Sell |
72,500
-38,900
| -35% | -$16.4M | 0.01% | 903 |
|
|
2023
Q4 | $45.3M | Buy |
111,400
+38,100
| +52% | +$14.1M | 0.01% | 728 |
|
|
2023
Q3 | $25.5M | Buy |
73,300
+53,000
| +261% | +$18.5M | 0.01% | 915 |
|
|
2023
Q2 | $7.14M | Sell |
20,300
-34,900
| -63% | -$11.8M | ﹤0.01% | 2286 |
|
|
2023
Q1 | $17.4M | Sell |
55,200
-49,000
| -47% | -$14.7M | 0.01% | 1105 |
|
|
2022
Q4 | $30.1M | Sell |
104,200
-36,500
| -26% | -$11.1M | 0.01% | 755 |
|
|
2022
Q3 | $40.7M | Sell |
140,700
-20,800
| -13% | -$5.98M | 0.02% | 614 |
|
|
2022
Q2 | $45.5M | Sell |
161,500
-58,000
| -26% | -$15.5M | 0.02% | 593 |
|
|
2022
Q1 | $57.3M | Sell |
219,500
-29,100
| -12% | -$6.91M | 0.02% | 622 |
|
|
2021
Q4 | $54.6M | Buy |
248,600
+8,700
| +4% | +$1.69M | 0.02% | 609 |
|
|
2021
Q3 | $43.5M | Hold |
239,900
| – | – | 0.02% | 663 |
|
|
2021
Q2 | $48.4M | Buy |
239,900
+15,500
| +7% | +$3.24M | 0.02% | 564 |
|
|
2021
Q1 | $48.2M | Buy |
224,400
+112,900
| +101% | +$24.8M | 0.02% | 489 |
|
|
2020
Q4 | $26.4M | Buy |
111,500
+49,300
| +79% | +$11.3M | 0.01% | 712 |
|
|
2020
Q3 | $16.9M | Sell |
62,200
-29,500
| -32% | -$8.14M | 0.01% | 864 |
|
|
2020
Q2 | $26.6M | Buy |
91,700
+77,900
| +564% | +$21.1M | 0.02% | 614 |
|
|
2020
Q1 | $3.28M | Sell |
13,800
-9,500
| -41% | -$2.18M | ﹤0.01% | 1545 |
|
|
2019
Q4 | $5.1M | Buy |
23,300
+8,200
| +54% | +$1.66M | 0.01% | 1080 |
|
|
2019
Q3 | $2.56M | Sell |
15,100
-300
| -2% | -$53.1K | ﹤0.01% | 1554 |
|
|
2019
Q2 | $2.82M | Sell |
15,400
-3,800
| -20% | -$664K | 0.01% | 1537 |
|
|
2019
Q1 | $3.53M | Sell |
19,200
-8,100
| -30% | -$1.5M | 0.01% | 1444 |
|
|
2018
Q4 | $4.52M | Buy |
27,300
+18,200
| +200% | +$3.15M | 0.01% | 1010 |
|
|
2018
Q3 | $1.75M | Buy |
9,100
+1,600
| +21% | +$285K | ﹤0.01% | 2051 |
|
|
2018
Q2 | $1.27M | Hold |
7,500
| – | – | ﹤0.01% | 2445 |
|
|
2018
Q1 | $1.22M | Buy |
7,500
+5,600
| +295% | +$915K | ﹤0.01% | 2409 |
|
|
2017
Q4 | $285K | Sell |
1,900
-26,900
| -93% | -$3.98M | ﹤0.01% | 3822 |
|
|
2017
Q3 | $4.38M | Buy |
28,800
+9,400
| +48% | +$1.41M | 0.01% | 960 |
|
|
2017
Q2 | $2.5M | Sell |
19,400
-61,700
| -76% | -$7.43M | 0.01% | 1287 |
|
|
2017
Q1 | $8.87M | Buy |
81,100
+77,600
| +2,217% | +$6.83M | 0.04% | 426 |
|
|
2016
Q4 | $258K | Sell |
3,500
-300
| -8% | -$24.4K | ﹤0.01% | 3504 |
|
|
2016
Q3 | $331K | Buy |
+3,800
| New | +$359K | ﹤0.01% | 3205 |
|
Other funds holding VRTX
VCM
VPM
Jane Street's VRTX Position: Q1 2026 in Review
Jane Street increased its Vertex Pharmaceuticals (VRTX) stake by 993% in Q1 2026, buying an estimated $52.1M and bringing the position to 122,946 shares worth $54.9M. The position accounts for 0.01% of the portfolio, ranked #990.
Jane Street first reported a position in VRTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $142M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Jane Street held 122,946 shares of Vertex Pharmaceuticals worth $54.9M as of Q1 2026.
- Jane Street bought 111,700 Vertex Pharmaceuticals shares in Q1 2026, an estimated $52.1M.
- Vertex Pharmaceuticals made up 0.01% of Jane Street's portfolio in Q1 2026, its #990 holding.
- Jane Street first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Jane Street's Vertex Pharmaceuticals position peaked at $142M in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.